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Aprior phase I/II trial of bortezomib/tacrolimus/methotrexate pro-phylaxis after human leukocyte antigen (HLA)-mismatchedreduced intensity conditioning allogeneic hematopoietic stem cell
transplantation documented low acute graft-versus-host disease inci-
dence, with promising overall and progression-free survival. 
We performed an open-label three-arm 1:1:1 phase II randomized con-
trolled trial comparing grade II-IV acute graft-versus-host disease
between conventional tacrolimus/methotrexate (A) versus bortezomib/
tacrolimus/methotrexate (B), and versus bortezomib/sirolimus/
tacrolimus (C), in reduced intensity conditioning allogeneic transplanta-
tion recipients lacking HLA-matched related donors. The primary end-
point was grade II-IV acute graft-versus-host disease incidence rate by
day +180. One hundred and thirty-eight patients (A 46, B 45, C 47) with
a median age of 64 years (range: 24-75), varying malignant diagnoses and
disease risk (low 14, intermediate 96, high/very high 28) received 7-8/8
HLA-mismatched (40) or matched unrelated donor (98) grafts. Median
follow up in survivors was 30 months (range: 14-46). Despite early
immune reconstitution differences, day +180 grade II-IV acute graft-ver-
sus-host disease rates were similar (A 32.6%, B 31.1%, C 21%; P=0.53
for A vs. B, P=0.16 for A vs. C). The 2-year non-relapse mortality inci-
dence was similar (A 14%, B 16%, C 6.4%; P=0.62), as were relapse (A
32%, B 32%, C 38%; P=0.74), chronic graft-versus-host disease (A 59%,
B 60% C 55%; P=0.66), progression-free survival (A 54%, B 52%, C
55%; P=0.95), and overall survival (A 61%, B 62%, C 62%; P=0.98).
Overall, the bortezomib-based regimens evaluated did not improve out-
comes compared with tacrolimus/methotrexate therapy. clinicaltrials.gov
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ABSTRACT
Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is curative in
advanced or aggressive hematologic malignancies despite associated toxicities.
While a sibling matched at human leukocyte antigen (HLA)-A, -B, -C, and -DRB1
is optimal, only a minority of patients who may benefit from HSCT have such a
donor available.1 Utilizing a 7/8 HLA-matched graft increases the likelihood of
obtaining an adult donor for all racial and ethnic groups,1 but at the expense of
worse outcomes. In reduced-intensity conditioning (RIC) HSCT, retrospective reg-
istry studies document increased rates of grade II-IV acute graft-versus-host disease
(aGvHD) and non-relapse mortality (NRM), with worse
progression-free survival (PFS) and overall survival (OS)
for 7/8 vs. 8/8 HLA-matched donors.2
The proteasome-inhibitor bortezomib (bort) can selec-
tively deplete proliferating alloreactive T lymphocytes,
reduce Th1 cytokines and Interleukin-6 levels, and block
antigen-presenting cell (APC) activation.3-6 It can also spare
regulatory T cells (Tregs) that are relevant in GvHD con-
trol.7 Administered early after graft infusion, short-course
bort can control GvHD in major histocompatibility com-
plex (MHC)-mismatched mouse HSCT and maintain
graft-versus-tumor responses,6,8,9 while avoiding the pro-
inflammatory colonic toxicity of delayed or prolonged
bort.5,8,10 
In a phase I/II study of RIC we documented that bort-
based GvHD prophylaxis (bort 1.3 mg/m2 IV on d +1, +4,
+7, plus conventional tacrolimus [tax] and methotrexate
[mtx]) was safe and potentially efficacious in T-replete
HLA-mismatched donor (MMD) transplantation, with
survival comparable to HLA-matched cohorts.11,12 These
data were used to support the inclusion of the bort-based
regimen as one novel arm of an ongoing multicenter phase
II randomized trial, comparing it to two other novel regi-
mens: post-transplant cyclophosphamide (PTCy), and
maraviroc, each compared to a non-randomized ‘conven-
tional care’ cohort (The Blood and Marrow Transplant
Clinical Trials Network [BMTCTN] 1203). 
We additionally conducted a phase II randomized con-
trol trial (RCT) for patients lacking 8/8 HLA-matched sib-
ling donors (DFCI 12-404), directly randomizing conven-
tional tac/mtx vs. two novel bort-based GvHD prophylax-
is regimens, whose mature results we report herein. The
regimens comprised bort plus tac/mtx (arm B), directly
based on our phase I/II data; and bort plus sirolimus
(sir)/tac (arm C), to explore the tolerizing effects of
enhanced Treg sparing with combined proteasome- and
mechanistic target of rapamycin (mTOR)-inhibition dur-
ing early immune reconstitution.7,13 We chose bort/sir/tac
instead of bort-based calcineurin inhibitors (CNI)-free pro-
phylaxis (e.g., bort/sir/mycophenolate mofetil [MMF]) as
the sir/MMF doublet has limited clinical efficacy,14 and in
our experience, adding bort to sir/MMF did not provide
adequate efficacy in GvHD prevention, while the sir/tac
doublet has documented efficacy comparable to conven-
tional tac/mtx.15
Methods
This prospective clinical trial was approved by the institutional
review board of the Dana-Farber Cancer Institute/Harvard Cancer
Center. Written informed consent was obtained prior to patient
enrollment.  
Study Design
The study was a one-stage randomized phase II trial with the
primary objective of comparing the incidence of aGvHD in two
bort-based GvHD prophylaxis regimens to conventional tac/mtx.
The study was designed for the primary comparisons of the grade
II-IV aGvHD rates in Arm A vs. B and Arm A vs. C in parallel, and
was powered to test the hypothesis of superiority in Arm B and C
(15%), compared to that in Arm A (40%). The accrual goal was
138 patients, randomizing all eligible patients in 1:1:1 ratio to the
three regimens. Randomization was stratified by degree of HLA-
match (8/8 vs. 7/8).   
Patients
Adult hematologic malignancy patients lacking an available
HLA-matched sibling with an available 8/8 (HLA-A, -B, -C, -
DRB1) matched unrelated donor (MUD) or 1-antigen/allele mis-
matched related donor (MMRD) or mismatched unrelated donor
(MMUD) were enrolled on the trial between January 2013 and
November 2015. Patients with HIV infection, active hepatitis B or
C disease, abnormal renal (serum creatinine > upper limit of nor-
mal [ULN] with clearance <40 mL/min/1.73m2  body surface area
[BSA]) or liver function (serum total bilirubin >ULN, serum ala-
nine/aspartate aminotransferase >2x ULN), Eastern Cooperative
Oncology Group (ECOG) performance status >2, hyperlipidemia
(serum cholesterol >300mg/dL; trigylcerides >400mg/dL) despite
therapy, and peripheral neuropathy ≥grade 2 within 21 days prior
to transplantation were excluded.  
Transplantation
Conditioning comprised busulfan (0.8 mg/kg twice daily IV)
and fludarabine (30 mg/m2 once daily IV) from days -5 to -2. T-
replete donor peripheral blood stem cells (PBSC) dosed at ≥ 2x106
CD34+ cells/kg were infused on day 0. GvHD prophylaxis regi-
mens were: tac/mtx (arm A), bort/tac/mtx (arm B), and bort/sir/tac
(arm C). Dosing was: bort (1.3 mg/m2 IV on day +1, +4, +7), mtx
(10 mg/m2 IV on day +1, 5 mg/m2 on day +3, +6, +11), sir (target
trough level 5-12 ng/ml) and/or tac (target trough level 5-10 ng/ml)
from day -3. The tapering of immunosuppression started at
around d+100, with the aim of being off immune suppression (IS)
by day +180, as applicable per treatment arm. 
Participants received levetiracetam for seizure prophylaxis from
day -5 to -1 and filgrastim 5 μg/kg daily from day +1 until an
absolute neutrophil count (ANC) >1500 cells/μl was attained, and
at least 12 months of Pneumocystis jiroveci and herpes simplex virus
(HSV)/ varicella zoster virus (VZV) prophylaxis. Anti-fungal pro-
phylaxis was not routine.
Immunophenotyping
CD4+ T cells were defined as CD3+CD4+; CD8+ T cells were
defined as CD3+CD8+; CD8+ naïve cells were defined as
CD8+CD45RO-CD62L+; CD4 Tregs were defined as
CD3+CD4+CD25med-highCD127low; CD4 conventional T cells (Tcons)
were defined as CD3+CD4+CD25low-negCD127med-high; natural killer
(NK) cells as CD56+CD3–; and B cells as CD19+. Aliquots of anti-
coagulated whole blood (ethylenediaminetetraacetic acid [EDTA])
were incubated with fluorophore-conjugated monoclonal anti-
bodies: anti-CD3 V450 (clone UCHT1, BD Biosciences), anti-CD4
APC-H7 (clone RPA-T4, BD Biosciences), anti-CD8 Pacific-Orange
(clone RPA-T8, Biolegend), anti-CD25 PE-Cy7 (clone M-A251, BD
Biosciences), anti-CD127 PE-Cy5 (clone eBioRDR5, eBioscience)
for T-cell subsets; anti-CD56 PE (clone B159, BD Biosciences),
anti-CD3 V450 (clone UCHT1, BD Biosciences) for NK/NKT cells,
and anti-CD19 APC (clone HIB19, BD Biosciences) for B cells.
RBC lysis with BD Pharm Lyse was performed either prior to or
following incubation with conjugated antibodies. Flow cytometry
analysis utilized FACSCanto II (BD Bioscience) or the Fortessa (BD
Bioscience) and FACSDiva software (BD Bioscience). There was a
change in the use of flow cytometry machines over the course of
the study. Both flow cytometers were validated and results were
comparable.  
Statistical considerations
The primary endpoint was a grade II-IV aGvHD rate by day 180
after stem cell infusion. Secondary endpoints included cumulative
incidence of aGvHD, NRM, relapse, chronic (c)GvHD, and PFS,
OS and GvHD-free/relapse-free survival (GRFS). The study was
designed for the primary comparisons of the grade II-IV aGvHD
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rates in arm A vs. B and arm A vs. C in parallel. We projected the
incidence of grade II-IV aGvHD as 40% in arm A and 15% in arm
B and in arm C. With the sample size of 46 per arm, there is an
80% power to detect a 25% difference in grade II-IV aGvHD rate
between two arms. This power calculation is based on Fisher’s
exact test at one-sided type I error rate of 0.05. The primary analy-
sis was performed per the modified intent-to-treat principle
(mITT), i.e., all patients who were randomized and received any
amount of the study treatment were included in the primary
analysis. Cumulative incidence of aGvHD and cGvHD, relapse
and NRM were estimated in the competing risk framework.
Relapse with or without death was considered a competing risk
for NRM, and similarly NRM for relapse. Death or relapse without
developing GvHD was a competing event for GvHD. GvHD inci-
dences occurring after relapse, in the setting of relapse interven-
tions (e.g., immunosuppression [IS] taper, donor lymphocyte infu-
J. Koreth et al.
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Table 1. Baseline characteristics of the study cohorts: by treatment arms A, B, C, and overall.
Arm A (N=46) Arm B (N=45) Arm C (N=47) All (N=138)
(Tac/Mtx) (Bort/Tac/Mtx) (Bort/Sir/Tac)
N % N % N % N % P
Age,  median (range) 65 (29, 74) 65 (30, 75) 62 (24, 73) 64 (24, 75) 0.13
Patient Sex 0.15
Male                        28 60.9 32 71.1 24 51.1 84 60.9
Female                      18 39.1 13 28.9 23 48.9 54 39.1
Donor Sex 0.75
Male                        32 69.6 33 73.3 36 76.6 101 73.2
Female                      14 30.4 12 26.7 11 23.4 37 26.8
Patient-Donor Sex Match                  0.39
MM 20 43.5 26 57.8 21 44.7 67 48.6
MF 8 17.4 6 13.3 3 6.4 17 12.3
FM 12 26.1 7 15.6 15 31.9 34 24.6
FF 6 13.0 6 13.3 8 17.0 20 14.5
ECOG Performance Status     0.11
0 7 15.2 10 22.2 10 21.3 27 19.6
1 21 45.7 20 44.4 30 63.8 71 51.4
2 18 39.1 15 33.3 7 14.9 40 29.0
Primary Disease             0.48
AML                         19 41.3 16 35.6 18 38.3 53 38.4
CLL/SLL/PLL                 5 10.9 3 6.7 3 6.4 11 8.0
CML                         - - 1 2.2 2 4.3 3 2.2
Hodgkin Disease             2 4.4 2 4.4 3 6.4 7 5.1
ALL                         3 6.5 - - 3 6.4 6 4.4
MDS                         12 26.1 12 26.7 9 19.2 33 23.9
MPD                         2 4.4 1 2.2 - - 3 2.2
Mixed MDS/MPD               - - 1 2.2 - - 1 0.7
NHL                         2 4.4 9 20.0 9 19.2 20 14.5
Other Acute Leukemia        1 2.2 - - - - 1 0.7
HLA Type 0.83
8/8 match 34 73.9 32 71.1 32 68.1 98 71.0
7/8 match 12 26.1 13 28.9 15 31.9 40 29.0
Patient-Donor  CMV Serostatus                     0.01
Positive                    36 78.3 35 77.8 25 53.2 96 69.6
Graft Source NA
PB 46 100 45 100 47 100 138 100
Disease Risk Index 0.94
Low 5 10.9 4 8.9 5 10.6 14 10.1
Intermediate 33 71.7 30 66.7 33 70.2 96 69.6
High/Very high 8 17.4 11 24.4 9 19.2 28 20.3
Tac: tacrolimus; Mtx: methotrexate; Bort: bortezomib; Sir: sirolimus; MM: male patient/male donor; MF: male patient/female donor; FM: female patient/male donor; FF: female
patient/female donor; AML: acute myeloid leukemia; CLL/SLL/PLL: chronic lymphocytic leukemia/small lymphocytic lymphoma/prolymphocytic leukemia; CML: chronic
myeloid leukemia; MDS: myelodysplastic syndromes; MPD: myeloproliferative syndromes; NHL: non-Hodgkin lymphoma; PB: peripheral blood; ALL: acute lymphoblastic
leukemia; HLA: human leukocyte antigen; CMV: cytomegalovirus.
sion [DLI]), were counted in the estimation of cumulative inci-
dence of GvHD in order to obtain comprehensive estimates, and
both inclusive and exclusive estimates are presented for aGvHD
endpoints. GRFS, PFS and OS were estimated using the Kaplan-
Meier method. GRFS was defined as the time from stem cell infu-
sion to incidence of grade III/IV aGvHD, cGvHD requiring sys-
temic immunosuppression agents, relapse or death, whichever
occured first. PFS and OS have been defined elsewhere.
Cumulative incidences in the presence of competing events were
compared using the Gray test, and Kaplan-Meier estimates were
compared using the log-rank test.16 For time-to-event endpoints, 
P-values reflect comparing entire distributions along with point
estimates for ease of presentation. For the primary endpoint, inci-
dence rates of grade II-IV aGvHD by day +180 were compared at
one-sided significance level of 0.05 using Fisher’s exact test; P-val-
ues for secondary endpoints are two-sided at the significance level
of 0.05, without adjusting for multiple comparisons. Multivariable
analysis adjusting for variables, as listed in Table 1, were per-
formed for OS and PFS using a Cox model, and a Fine and Gray
model was used for grade II-IV aGvHD.17 Immunophenotype data
were compared using the Wilcoxon rank-sum test at each time
point without adjusting for multiple comparisons. All statistical
analyses were performed using SAS version 9.3 (SAS Institute,
Cary, NC, USA) and R version 3.1.3 (the CRAN project).
Results
Patient and transplant variables: one hundred and forty-
two subjects enrolled and 138 randomized subjects were
evaluable per the protocol-specified mITT criteria (four
cancelled study participation before receiving transplanta-
tion conditioning: two due to acute infection (one with
subsequent disease relapse), one due to provider prefer-
ence to continue protocol-excluded medications, and
another due to disease relapse at transplantation admis-
sion) (Figure 1). The treatment arms (A 46, B 45, C 47)
were balanced for pre-transplant variables (Table 1),
except lower cytomegalovirus (CMV) seropositivity in
arm C (A, 78.3% vs. B, 77.8% vs. C, 53.2%, P=0.01).
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Figure 1. CONSORT Diagram. *1 patient
with relapse and infection. Tac: tacrolimus;
Mtx: methotrexate; Bort: bortezomib; Sir:
sirolimus.
Table 2. Summary of the primary endpoint
(A) aGvHD after relapse with IS taper included
Arm P
A (Tac/MTX) B (Bort/Tac/MTX) C (Bort/Sir/Tac) A vs. B A vs. C
Day 180  aGvHD rate*
grade II-IV  (LL, UL) 32.6%(21.3, 45.7) 31.1%(19.9, 44.3) 21% (12, 33.4) 0.53 (1.0) 0.16 (0.25)
grade III-IV  (LL, UL) 2.2% (0.1, 9.9) 8.9% (3.1, 19.2) 14.9% (7.2, 26.2) 0.97 (0.2) 0.997 (0.06)
(B) aGvHD after relapse with IS taper excluded
Day 180  aGvHD rate*
grade II-IV  (LL, UL) 32.6%(21.3, 45.7) 28.9% (18, 42) 14.9% (7.2, 26.2) 0.44 (0.82) 0.04 (0.054)
grade III-IV  (LL, UL) 2.2% (0.1, 9.9) 8.9% (3.1, 19.2) 10.6% (4.3, 21.1) 0.97 (0.2) 0.99 (0.2)
*proportion of aGvHD at Day +180. **P-values without parenthesis indicate one-sided testing of whether the aGvHD rate in arm B or C is lower than the aGvHD rate in arm A.
P-values in parenthesis indicate two-sided testing. UL: upper one-sided confidence limit at 5% level; LL: lower one-sided confidence limit at 5% level; aGvHD: acute graft-versus-
host disease; Tac: tacrolimus; Mtx: methotrexate; Bort: bortezomib; Sir: sirolimus.
Subjects had a median age of 64 years (range: 24-75), vary-
ing diagnoses (53 acute myeloid leukemia [AML], 33
myelodysplastic syndrome [MDS], 20 non-Hodgkin lym-
phoma [NHL], 11 chronic lymphocytic leukemia [CLL],
etc.) and disease-risk indices (low 14, intermediate 96,
high/very high 28). They received T-replete 8/8 MUD
(n=98) or 7/8 MMD (n=40) PBSC grafts. Median follow up
in survivors was 30 months (range: 14-46). 
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Table 3. Summary of the secondary endpoints
Arm P
A (Tac/MTX) B (Bort/Tac/MTX) C (Bort/Sir/Tac) A vs. B A vs. C A vs. B vs. C
Day 180  aGvHD*  (a)
grade II-IV (95% CI) 33%(20, 47) 31%(18, 45) 21% (11, 34) 0.71 0.33 0.36
grade III-IV (95% CI) 2.2% (0.2, 10) 8.9% (2.8, 19) 15% (6.5, 27) 0.64 0.07 0.1
Day 180  aGvHD* (b)
grade II-IV (95% CI) 33%(20, 47) 29%(16, 43) 15% (6.5, 27) 0.54 0.11 0.15
grade III-IV (95% CI) 2.2% (0.2, 10) 8.9% (2.8, 19) 11% (3.8, 21) 0.64 0.2 0.6
2y  cGvHD* 
All cGvHD (95% CI) 59% (43, 72) 60% (43, 73) 55% (39, 68) 0.9 0.43 0.66
Ext cGvHD (95% CI) 39% (24, 53) 49% (33, 64) 48% (33, 62) 0.37 0.57 0.64
2y NRM* (95% CI) 14% (5, 26) 16% (7, 29) 6.4% (1.6, 16) 0.92 0.42 0.62
2y Relapse* (95% CI) 32% (18, 46) 32% (19, 47) 38% (24, 52) 0.64 0.75 0.74
2y PFS (95% CI) 54% (38, 68) 52% (35, 65) 55% (40, 68) 0.76 0.87 0.95
2y OS (95% CI) 61% (45, 74) 62% (45, 74) 62% (46, 74) 0.96 0.9 0.98
*cumulative incidence. P-values for cumulative incidence, PFS and OS are from Gray’s test and log-rank test measuring the difference of entire distributions between two groups.
All P-values are two-sided. (a): aGvHD after relapse with IS taper included; (b): aGvHD after relapse with IS taper excluded; aGvHD: acute graft-versus-host disease; cGvHD: chronic
graft-versus-host disease; Ext: extensive; IS: immunosuppression; NRM: non-relapse mortality; PFS: progression-free survival; OS: overall survival; CI: confidence interval; Tac:
tacrolimus; Mtx: methotrexate; Bort: bortezomib; Sir: sirolimus.
Figure 2. aGvHD: non-relapse mortality and relapse outcomes. Cumulative incidence of (A) grade II-IV aGvHD*, (B) grade III-IV aGvHD*, (C) non-relapse mortality
(NRM), and (D) relapse per treatment arm. Black indicates arm A (tac/mtx), red indicates arm B (bort/tac/mtx), and blue indicates arm C (bort/sir/tac). Gray’s test
for comparing the entire distributions was used. *: Acute graft-versus-host disease (GvHD) after relapse with IS taper included. Tac: tacrolimus; Mtx: methotrexate;
Bort: bortezomib; Sir: sirolimus.
A
C
B
D
P=0.36
Grade II-IV Acute GvHD Grade III-IV Acute GvHD
P=0.1
P=0.74P=0.62
Engraftment, chimerism, safety: the median time to neu-
trophil (>500/μl) and platelet engraftment (>20,000/μl)
among patients who experienced count nadir (i.e., neu-
trophil count <500/vl and/or platelet count <20,000/μl)
was 11 days (range: 2-45) and 19 days (range: 10-57),
respectively, with no significant difference between treat-
ment arms (P=0.9 and P=0.55 for neutrophils and
platelets, respectively). For the entire cohort, 31% of
patients did not experience count nadir (24% in arm A,
27% in arm B, 43% in arm C, P=0.11) and no subject
failed neutrophil engraftment. Median total nucleated cell
donor chimerism by day 30 was 96% (range: 42-100) and
by day 100 was 97% (range: 0-100, with no significant dif-
ference between treatment arms (P=0.84 and P=0.83,
respectively). The bort-based regimens were well tolerat-
ed. No bort doses were delayed or reduced due to toxicity.
No serious adverse event (SAE) attributable to bort (e.g.,
neuropathy) was documented. Common Terminology
Criteria for Adverse Events (CTCAE) grade ≥3 organ dys-
function (hepatic, renal, pulmonary) did not differ signifi-
cantly between treatment arms, including the incidence of
acute kidney injury (AKI, 8.7% overall), thrombotic
microangiopathy/hemolytic-uremic syndrome
(TMA/HUS, 6.5% overall) or hepatic veno-occlusive dis-
ease (VOD, 3.3% overall) (P=0.14, P=0.16 and P=0.41,
respectively).
Acute GvHD: The primary endpoint of grade II-IV
aGvHD incidence rate by day +180 did not differ signifi-
cantly between treatment arms, at 32.6% (A) vs. 31.1% (B,
one-sided P=0.53 for arm A vs. B) vs. 21% (C, one-sided
P=0.16 for arm A vs. C) (Table 2). This result is consistent
with the cumulative incidence of aGvHD (P=0.36) (Table
3, Figure 2A).  For seven patients, grade II-IV aGvHD
occurred after hematologic malignancy relapse (six after
early IS taper, and 1 after donor lymphocyte infusions
[DLI]). Four of these (B, 1; C, 3) had aGvHD onset prior to
day +180, and are included in the primary endpoint. This
result was consistent with the result from multivariable
analysis: subdistribution hazard ratio (sHR) was 0.87
(95% confidence interval [CI] 0.42-1.78, P=0.7) for arm B
vs. arm A, and 0.68 (95% CI 0.33-1.4, P=0.29) for arm C
vs. arm A. If patients with aGvHD onset after relapse are
excluded from the analysis, the grade II-IV aGvHD inci-
dence rate by day +180 was 32.6% (A) vs. 28.9% (B, one-
sided P=0.44 for arm A vs. B) vs. 14.9% (C, one-sided
P=0.04 for arm A vs. C) (Table 2). On multivariable analy-
sis, sHR was 0.8 (95% CI 0.39-1.66, P=0.55) for arm B vs.
A, and 0.53 (95% CI 0.23-1.18, P=0.12) for arm C vs. A.
aGvHD incidence continued to rise after day +180 across
arms, and the 1-year cumulative incidence of grade II-IV
aGvHD was 40% in arm A, 34% in arm B, and 26% in
arm C (P=0.71 for arm A vs. B, P=0.33 for arm A vs. C)
(Figure 2A). For grade III-IV severe aGvHD, day +180
cumulative incidence  was 2.2% (A) vs. 8.9% (B, P=0.64
for arm A vs. B) vs. 15% (C, P=0.07 for arm A vs. C) (Table
3, Figure 2B).  
In an exploratory analysis in line with our protocol strat-
ification, we repeated the analysis by HLA match status
(Online Supplementary Table S1A). For the 8/8 HLA-
matched recipients, when all grade II-IV aGvHD were
counted, the six-month cumulative incidence was 33%
(A) vs. 16% (B, P=0.1 for arm A vs. B) vs. 19% (C, P=0.21
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Figure 3. cGvHD: survival and GRFS
outcomes. Cumulative incidence of (A)
all cGvHD, and Kaplan-Meier survival
plots of (B) progression-free survival
(PFS), (C) overall survival (OS), and (D)
grade III-IV aGvHD/cGvHD requiring sys-
temic IS agents/relapse-free survival
(GRFS) per treatment arm. Black indi-
cates arm A (tac/mtx), red indicates
arm B (bort/tac/mtx), and blue indi-
cates arm C (bort/sir/tac). Tac:
tacrolimus; Mtx: methotrexate; Bort:
bortezomib; Sir: sirolimus; GvHD: graft-
versus-host disease. 
A
C
B
D
P=0.95
P=0.53
P=0.98
P=0.66
All chronic GvHD
GvHD-free, relapse-free survival
for arm A vs. C) (Online Supplementary Figure S1). When
arms B and C were combined, the six-month cumulative
incidence was 17% (P=0.08 for arm A vs. arm B or C).
When we repeated the analysis after excluding aGvHD
that occurred after relapse and IS taper, the six-month
cumulative incidence was 33% (A) vs. 13% (B, P=0.046 for
arm A vs. B) vs. 16% (C, P=0.13 for arm A vs. C). When
arms B and C were combined, the cumulative incidence
was 15% (P=0.03 for arm A vs. arm B or C). However, for
7/8 MMD recipients such a benefit was not appreciable
(albeit with limited sample size) (Online Supplementary
Table S1A, Online Supplementary Figure S1). 
NRM, relapse, chronic GvHD, and survival: NRM did not
differ significantly between treatment arms (Table 3), with
a 2-year cumulative incidence of 14% (A, 95% CI, 5-26)
vs. 16% (B, 95% CI, 7-29) vs. 6.4% (C, 95% CI, 1.6-16;
P=0.62) (Figure 2C). Relapse did not differ significantly
between treatment arms, with a 2-year cumulative inci-
dence of 32% (A, 95% CI, 18-46) vs. 32% (B, 95% CI, 19-
47) vs. 38% (C, 95% CI, 24-52; P=0.74) (Figure 2D). The 2-
year cumulative incidence of cGvHD did not differ signif-
icantly between treatment arms, at 59% (A) vs. 60% (B) vs.
55% (C; P=0.66) (Figure 3A). For five patients, cGvHD
occurred after documented hematologic malignancy
relapse (A, 1; B, 2; C, 2) and these were included in the
estimation of cumulative incidence of cGvHD. Two had
early IS taper, none received DLI. The 2-year PFS did not
differ significantly between treatment arms, at 54% (A) vs.
52% (B) vs. 55% (C; P=0.95) (Figure 3B). The 2-year OS
did not differ significantly between treatment arms, at
61% (A) vs. 62% (B) vs. 62% (C; P=0.98) (Figure 3C). The
composite 2-year GRFS endpoint did not differ significant-
ly between treatment arms, at 11% (A) vs. 12% (B) vs. 8%
(C; P=0.53) (Figure 3D). 
Immune reconstitution: The median total CD3+ T-cell
count/µl at one month after transplantation was 401 in
arm A (Q1-Q3, 248-681) vs. 414 in arm B (Q1-Q3, 195-
898) vs. 190 in arm C (Q1-Q3, 137-340; P<0.0001), and
remained lower in arm C through months two and three
(A, 602 and 728 vs. B, 639 and 571 vs. C, 221 and 269,
respectively; P<0.0001). At six months after transplanta-
tion, CD3+ T-cell counts were similar in all three arms at
763 (A, Q1-Q3, 463-1120) vs. 535 (B, Q1-Q3, 333-907) vs.
508 (C, Q1-Q3, 322-728; P=0.10) (Figure 4A). This reflect-
ed both a lower median CD8+ and CD4+ T-cell count/μl at
one to three months after transplantation in arm C
(P<0.0001, data not shown). Similarly, the median CD19+ B-
cell and the median CD56+CD3– NK cell count/μl was
lower for arm C during the one to three months following
transplantation (P<0.05, data not shown). 
While the total CD4+ Tcon cell count/μl at one, two, and
three months after transplantation was lower for arm C
(P=0.005, P=0.0006, P=0.024 at one, two and three
months after transplantation, respectively), the total CD4+
Treg cell count/µl was unimpaired in arm C at those time
points, resulting in an improved ratio of Treg:Tcon recon-
stitution at one and three months after transplantation (A:
0.049 and 0.05 vs. B: 0.051 and 0.032 vs. C: 0.088 and
0.067; P=0.006 and P=0.012, respectively) (Figure 4B).  
Discussion 
Most adult hematologic malignancy patients who may
benefit from allogeneic HSCT lack an available sibling
donor and are considered for a MUD or 1-locus MMD,
with umbilical cord blood (UCB) and haploidentical
(haplo) donors being additional alternative options.
Regarding 8/8 MUD, as a result of improvements in DNA-
based typing and supportive care, survival outcomes are
considered similar to those of MRD HSCT,18,19 although
studies indicate that MUD HSCT is associated with
increased grade II-IV aGvHD (52% vs. 34%), grade III-IV
aGvHD (21% vs.16%), and NRM (RR 2.76; P<0.01).20 The
use of 1-locus MMD adds risk. A large registry analysis of
2,588 patients with acute leukemias, MDS or chronic
myeloid leukemia (CML) undergoing RIC HSCT com-
pared 7/8 with 8/8 HLA-matched donors, and document-
ed higher rates of grade II-IV aGvHD and NRM, and lower
3-year OS (30% vs. 38%, respectively; P=0.01) with a mis-
matched graft.2 Novel regimens to improve GvHD out-
comes for patients lacking a preferred sibling donor would
represent a major advance, and is the focus of our efforts.
Proteasome inhibition with bort has immunomodulato-
ry properties relevant to allogeneic HSCT, as previously
highlighted. Based on encouraging phase I/II results in
J. Koreth et al.
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Figure 4. Immune reconstitution outcomes. Reconstitution of (A) median of
absolute CD3+ T-cell count/μL, and (B) median values of CD4+ Treg:Tcon cell
ratio per treatment arm. Blue indicates arm A (tac/mtx), red indicates arm B
(bort/tac/mtx), and green indicates arm C (bort/sir/tac). Treg: regulatory 
T cells; Tcon: conventional T cells; Tac: tacrolimus; Mtx: methotrexate; Bort:
bortezomib; Sir: sirolimus; W1: week 1; W2: week 2; M: month.
A
B
Absolute CD3+ T-cell count per μL
Treg: Tcon Ratio
HLA-mismatched T-replete RIC HSCT, we undertook a
prospective randomized evaluation of aGvHD prophylax-
is with conventional tac/mtx (arm A) vs. two novel regi-
mens of short-course bort for transplantation recipients
lacking 8/8 HLA-matched related donors: bort plus
tac/mtx (arm B), and bort plus sir/tac (arm C).
In our study, Bort, limited to three doses peritransplan-
tation (day +1, +4 and +7), did not add toxicity. No bort
doses were missed or modified. No subjects developed
toxicities of prolonged/delayed bort administration (e.g.,
neuropathy, colonic necrosis). Comparing treatment arms,
no increase in hepatic VOD, AKI or TMA/HUS was noted
for bort-based regimens vs. tac/mtx. 
Engraftment was rapid and sustained, with robust
donor chimerism by day 30 that was sustained and com-
parable across treatment arms. The addition of bort alone
did not appear to impair immunologic recovery, with sim-
ilar counts of T cells (CD4, CD8), B cells and NK cells in
the conventional tac/mtx vs. bort/tac/mtx arms. Count
recovery for arm C (bort/sir/tac) was lower, as we previ-
ously documented for other sir-based cohorts.10 As
hypothesized, there was relative sparing of Treg reconsti-
tution with arm C (bort/sir/tac), with no impairment of
Treg count recovery and elevated Treg:Tcon ratios. 
The clinical impact of these systematic immunologic dif-
ferences, however, remains unclear. Importantly, the 2-year
NRM incidence was low (ranging from 6.4% to 16%) and
did not differ significantly between treatment arms. Relapse
was in the expected range after RIC HSCT (ranging from
24% to 36%), and did not differ significantly between treat-
ment arms. In this study, survival, while not differing signif-
icantly between treatment arms, with 2-year OS ranging
from 61% to 62% (P=0.98), appeared better than anticipat-
ed for 7/8 and 8/8 HLA-matched recipients, plateauing at
50% and 66%, respectively, in contrast to 1- and 3-year reg-
istry benchmark survivals recently reported for 7/8 and 8/8
donor recipients, of 48%→30% and 55%→38%, respec-
tively.2 We highlight a lack of significant difference between
treatment arms with regard to the primary endpoint of
grade II-IV aGvHD rate by day +180.
In the context of delayed T-cell reconstitution noted for
arm C, this suggests that the combination of a CNI (tac)
plus mTOR inhibitor (sir) provides IS without long term
tolerizing effects. While it is possible that longer duration
of tac/sir immunosuppression in arm C beyond day +180
may have better prevented aGvHD, ultimately, aGvHD
deferral rather than long-term amelioration remains a pos-
sibility. In subgroup analysis for the 8/8 HLA-matched
recipients, bort-based regimens had a borderline trend
towards grade II-IV aGvHD benefit vs. tac/mtx, with a
cumulative incidence of 17% vs. 33%, respectively,
(P=0.08). However, grade III-IV severe aGvHD rates were
not improved, and for 7/8 MMD grafts a similar trend for
aGvHD benefit of bort-based regimens was not apprecia-
ble, though sample size was limited. 
Our trial has strengths due to its appropriate size in the
phase II context, and its direct prospective randomization
to conventional tac/mtx vs. two novel bort-based GvHD
prophylaxis regimens. Concerns regarding open-label
treatment assignment are ameliorated by the minimal
dropout rate and the mITT analysis to further avoid bias,
while the ‘hard’ endpoints of GvHD, NRM, relapse and
survival additionally obviate assessment bias concerns. 
Our primary finding is that, as tested, bort-based regi-
mens did not appear to provide additional benefit for
grade II-IV aGvHD prevention in T-replete PBSC RIC
HSCT, failing to meet the protocol-specified 25% reduc-
tion in aGvHD incidence for success. Our phase II RCT
requirements for success were stringent, which limits our
ability to detect lower, albeit potentially clinically mean-
ingful benefit with bort. However, it is also notable that
conventional tac/mtx outcomes were better than antici-
pated, a finding similar to that recently reported in other
contemporary randomized HSCT trials.21 
These data highlight the inadequacy of non-randomized
comparators for evaluating early phase single arm inter-
ventional studies, and document, as an updated standard,
the improved MMD and MUD RIC HSCT outcomes
achievable with conventional tac/mtx in this study (2-year
OS of 58% and 62%, respectively). In the future, prospec-
tive trials of alternative donors (e.g., UCB, haplo) and
novel GvHD prophylaxis regimens (e.g., maraviroc,
PTCy) may need to benchmark these outcomes. In con-
trast, the bar for the novel GRFS endpoint appears far
lower, ranging from 8% to 12% in our study, with no sig-
nificant difference between treatment arms (P=0.53).
In summary, mature data from this open-label 1:1:1
three-arm phase II RCT indicates that the bort-based reg-
imens evaluated appear to provide lower than anticipated
grade II-IV aGvHD benefit compared to conventional
tac/mtx in T-replete PBSC RIC HSCT. While we note the
potential benefit of bort for 8/8 HLA-matched transplants,
direct phase III prospective randomization is required in
order to confirm such a benefit. Overall, however, the lack
of benefit for other transplantation outcomes (NRM,
relapse, chronic GvHD, and survival) suggests limited util-
ity for bort prophylaxis in the doses and combinations
assessed. Alternative proteasome inhibitor combination
regimens (e.g., with PTCy) should also be considered.  
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